主动脉弓缩窄诱导大鼠心肌肥大Raf/MEK/ERK通路的变化

doi:10.12047/j.cjap.5834.2020.007

摘要/Abstract

摘要： 目的:通过观察心肌肥大大鼠加速纤维肉瘤/丝裂素活化蛋白激酶激酶/胞外信号调节蛋白激酶(Raf/MEK/ERK)通路关键因子的基因和蛋白表达及蛋白磷酸化修饰水平上的变化,了解Raf/MEK/ERK通路在心肌肥大调控中的作用。方法: 20只SD大鼠随机分为假手术组和模型组,通过主动脉弓缩窄(TAC)法建立心肌肥大模型,12周后颌下静脉取血分离血清,检测氨基末端脑钠肽前体(NT-proBNP)含量,之后进行超声心动图测定和麻醉下的血流动力学测定,收集心肌标本,观察心肌组织的病理学改变,检测心肌组织Raf/MEK/ERK通路的关键因子基因、蛋白表达水平及蛋白磷酸化水平的变化。结果:与假手术组比较,TAC模型组大鼠超声心动图的左室舒张末期室间隔厚度(IVSd)、左室收缩末期室间隔厚度(IVSs)、左室后壁舒张末期厚度(LVPWd)、左室后壁收缩末期厚度(LVPWs)显著增厚(P＜0.05,P＜0.01),左室收缩末期内径(LVIDs)显著减小(P＜0.01),左心室质量(LV Mass)、左心系数LW(LV Mass/Weight)比值显著增加(P＜0.05,P＜0.01);大鼠心率(HR)、左心室最大收缩速率(+dp/dtmax)、左心室最大舒张速率(-dp/dtmax) 均显著降低(P＜0.01),血清中NT-pro BNP含量显著增加(P＜ 0.01);心肌细胞排列杂乱,心肌细胞肥大、胞质明显增多,炎症细胞浸润,出现大量胶原纤维沉积,大面积心肌细胞呈现蓝色;大鼠心肌组织中c-Raf在Ser259和Ser338上的磷酸化蛋白phospho-c-Raf (Ser259)和phospho-c-Raf (Ser338) 表达水平显著升高(P＜0.01),其下游MEK1/2、ERK1/2的磷酸化蛋白phospho-MEK1/2(Ser217/Ser221)和phospho-ERK1/2 (Thr202/Tyr204)表达水平也显著增高(P＜0.01)。结论: Raf/MEK/ERK通路在心肌肥大中的调控作用,可能通过激活关键因子c-Raf、MEK1、MEK2、ERK1和ERK2特异性位点的磷酸化实现的。

关键词: 大鼠, Raf/MEK/ERK通路, 心肌肥大, 主动脉弓缩窄, 调控机制

Abstract: Objective:To investigate the mRNA, protein expression levels and the phosphorylation levels of key factors in rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase/extracellular regulated protein kinases (Raf/MEK/ERK) pathway, and to clarify the regulatory function of Raf/MEK/ERK pathway in myocardial hypertrophy. Methods: Twenty SD rats were divided into sham-operated group and model group. The myocardial hypertrophy model was established by transverse aortic constriction (TAC). At 12 weeks after TAC, blood samples were collected from the submandibular vein, and the serum was separated to detect the content of N terminal pro B type natriuretic peptide (NT-proBNP). After that, the rats were subjected to echocardiography and hemodynamic measurement. Then the pathological changes of myocardial tissue were observed. And the levels of mRNA, protein expression and the phosphorylation of key factors in Raf/MEK/ERK pathway were detected in myocardial tissue.Results: Compared with sham-operated group, left ventricular end-diastolic interventricular septal thickness (IVSd), left ventricular end-systolic interventricular septal thickness (IVSs), left ventricular end-diastolic posterior wall thickness (LVPWd) and left vebtricular end-systolic posterior wall thickness (LVPWs) in TAC model group were increased significantly (P＜0.05,P＜0.01), left ventricular end-systolic diameter (LVIDs) was decreased significantly (P＜0.01), LV Mass and LW(LV Mass/Weight)were increased significantly (P＜0.05, P＜0.01). The levels of heart rate (HR), left ventricular pressure maximal rate of rise (+dp/dtmax), left ventricular pressure maximal rate of fall (-dp/dtmax) were decreased significantly (P＜0.01). The serum level of NT-proBNP in TAC rat was increased significantly (P＜0.01). The myocardial cells in TAC model group were arranged disorderly, myocardial cell hypertrophy, cytoplasm were increased significantly, and inflammatory cells infiltrated. A large amount of collagen fibers were deposited and large area of myocardial cells were stained blue in TAC rat. The expression levels of phospho-c-Raf (Ser259) and phospho-c-Raf (Ser338) in myocardial tissue were significantly increased (P＜0.01), meanwhile the expression levels of phospho- MEK1/2(Ser217/Ser221) and phospho-ERK1/2 (Thr202/Tyr204) were also significantly increased (P＜0.01).Conclusion: The regulatory role of Raf / MEK / ERK pathway in cardiac hypertrophy may be through the activation of phosphorylation of c-raf, MEK1, Mek2, ERK1 and ERK2 at specific sites.

Key words: rat, Raf/MEK/ERK pathway, cardiac hypertrophy, transverse aortic constriction, regulatory mechanism

富丹婷, 屠珏, 蔡月琴, 蔡兆伟, 张利棕, 刘景艳, 徐山春, 王德军. 主动脉弓缩窄诱导大鼠心肌肥大Raf/MEK/ERK通路的变化[J]. 中国应用生理学杂志, 2020, 36(1): 33-38.

FU Dan-ting, TU Jue, CAI Yue-qin, CAI Zhao-wei, ZHANG Li-zong, LIU Jing-yan, XU Shan-chun, WANG De-jun. The regulatory mechanism of Raf/MEK/ERK pathway on the rat cardiac hypertrophy induced by transverse aortic constriction[J]. CJAP, 2020, 36(1): 33-38.

参考文献 15

[1]	Samak M, Fatullayev J, Sabashnikov, A, et al. Cardiac hypertrophy: an introduction to molecular and cellular basis[J]. Med Sci Monit Basic Res, 2016, 22: 75-79.
[2]	Tham, YK, Bernardo BC, Ooi JY, et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets[J]. Arch Toxicol, 2015, 89(9): 1401-1438.
[3]	Yan K, Wang K, Li P. The role of post-translational modifications in cardiac hypertrophy[J]. J Cell Mol Med, 2019, 23(6): 3795-3807.
[4]	Zhang QJ, Tran TAT, Wang M, et al. Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis [J]. Nat Commun, 2018, 9(1): 5230.
[5]	Nomura S, Satoh M, Fujita T, et al. Cardiomyocyte gene programs encoding morphological and functional signatures in cardiac hypertrophy and failure[J]. Nat Commun, 2018, 9(1): 4435.
[6]	Gallo S, Vitacolonna A, Bonzano A, et al. ERK: a key player in the pathophysiology of cardiac hypertrophy [J]. Int J Mol Sci, 2019, 20(9): 2164-2184.
[7]	Zhang Y, Zhang L, Fan X, et al. Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/ β-catenin and Jak2/Stat3 pathways[J]. Biomed Pharmacother, 2019, 113: 108780.
[8]	Ju S, Park S, Lim L, et al. Low density lipoprotein receptor-related protein 1 regulates cardiac hypertrophy induced by pressure overload[J]. Int J Cardiol, 2020, 299: 235-242.
[9]	李依琪, 李乐. 青藤碱对异丙肾上腺素诱导小鼠心肌肥厚的影响[J]. 中国病理生理杂志, 2018, 34(6): 547-549.
[10]	Kresoja KP, Schmidt G, Kherad B, et al. Acute and chronic heart failure[J]. Herz, 2017, 42(7): 699-712.
[11]	Nakagawa Y, Nishikimi T, Sakai H, et al. Macro-pro-B-type natriuretic peptide (proBNP) and hidden macro-N-terminal proBNP: Case report [J]. Clin Biochem, 2018, 52: 148-152.
[12]	Courand PY, Harbaoui B, Bècle C, et al. Plasma NT-proBNP mirrors the deleterious cardiovascular and renal continuum in hypertension [J]. Eur J Prev Cardiol, 2017, 24(5): 452-459.
[13]	Tamura S, Marunouchi T, Tanonaka K. Heat-shock protein 90 modulates cardiac ventricular hypertrophy via activation of MAPK pathway [J]. J Mol Cell Cardiol, 2019, 127: 134-142.
[14]	Sala V, Gallo S, Gatti S, et al. Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib[J]. J Mol Cell Cardiol, 2016, 93: 84-97.
[15]	Li C, Chen Z, Yang H, et al. Selumetinib, an oral anti-neoplastic drug, may attenuate cardiac hypertrophy via targeting the erk pathway [J]. PLoS One, 2016, 11(7): e0159079.